Harvard Bioscience (NASDAQ:HBIO) Stock Price Passes Above 200 Day Moving Average – Here’s What Happened

Harvard Bioscience, Inc. (NASDAQ:HBIO) shares crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $6.13 and traded as high as $8.15. Harvard Bioscience shares last traded at $8.15, with a volume of 15,589 shares trading hands.

Analyst Ratings Changes

Several research analysts recently commented on HBIO shares. Benchmark raised their price target on shares of Harvard Bioscience from $6.00 to $7.50 and gave the stock a “speculative buy” rating in a research note on Wednesday, August 12th. Weiss Ratings cut shares of Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $6.75.

Harvard Bioscience Trading Down 1.5%

The company has a quick ratio of 0.98, a current ratio of 1.87 and a debt-to-equity ratio of 4.94. The stock’s 50 day moving average is $6.82 and its two-hundred day moving average is $6.14. The company has a market capitalization of $36.54 million, a PE ratio of -3.48 and a beta of 1.53.

Harvard Bioscience (NASDAQ:HBIO) last posted its earnings results on Tuesday, August 11th. The medical instruments supplier reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. Harvard Bioscience had a negative net margin of 11.86% and a negative return on equity of 33.13%. The business had revenue of $22.73 million for the quarter, compared to the consensus estimate of $21.45 million.

Institutional Trading of Harvard Bioscience

Hedge funds have recently bought and sold shares of the stock. Corsair Capital Management L.P. increased its holdings in shares of Harvard Bioscience by 1,008.7% in the 4th quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier’s stock valued at $741,000 after acquiring an additional 1,008,692 shares during the period. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Harvard Bioscience during the 4th quarter worth $401,000. Meros Investment Management LP boosted its position in Harvard Bioscience by 32.6% during the fourth quarter. Meros Investment Management LP now owns 1,217,628 shares of the medical instruments supplier’s stock valued at $814,000 after purchasing an additional 299,369 shares in the last quarter. Two Sigma Investments LP boosted its position in Harvard Bioscience by 139.7% during the third quarter. Two Sigma Investments LP now owns 474,157 shares of the medical instruments supplier’s stock valued at $208,000 after purchasing an additional 276,372 shares in the last quarter. Finally, Strs Ohio purchased a new position in Harvard Bioscience in the first quarter valued at about $117,000. Hedge funds and other institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.